시장보고서

상품코드

1906680

예측 유전자 검사 시장 규모와 예측(2021-2031년) - 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 : 유형별, 질환별, 최종사용자별, 지역별

Predictive Genetic Testing Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Disease, End User, and Geography

발행일: 2025년 12월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 205 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

예측 유전자 검사 시장은 2024년 14억 2,000만 달러에서 2031년까지 42억 달러에 이를 것으로 예측되고 있으며, 2025년부터 2031년에 걸쳐 CAGR 17.1%로 확대될 것으로 예측됩니다. 시장 성장을 가속하는 주요 요인에는 유전성 질환 유병률 상승, 맞춤형 의료에의 인지도와 수용성 향상, 소비자용 직접 판매(DTC) 유전자 검사 수요 급증등을 들 수 있습니다.이것들이 예측 유전자 검사 보급을 촉진하고 있습니다. 또한 희귀질환 및 보인자 스크리닝 구상에 대한 수용성과 자금 제공 증가가 예측 기간중 시장 성장을 가속 한다고 전망됩니다.그렇지만, 예측 유전자 검사 사회적·윤리적 영향, 유전자 검사 서비스 고비용, 엄격한 규제 요건 및 지연 하는 제품 승인 프로세스등이 시장 성장 억제요인으로서 들 수 있습니다.

미국에서는 예측 유전자 검사가 소비자 건강 관리와 임상 의료에 깊이 통합되어 있습니다. 23andMe, Myriad Genetics, Invitae와 같은 대형 유전체 기업들을 중심으로 세계 선두를 달리고 있습니다. 유전자정보차별금지법(GINA)은 건강 보험이나 고용에서 유전적 위험에 따른 차별로부터 개인을 보호하고, 예측 검사의 이용을 촉진하고 있습니다. 그러나 소비자 대상 유전자 검사는 여전히 감시의 대상이 되고 있습니다. 2025년에는 23andMe가 파산 절차 중에 고객의 유전자 데이터를 판매하려는 계획을 둘러싸고 20개 이상의 주에서 23andMe를 제소하여 데이터 프라이버시에 대한 우려를 불러일으켰습니다. 한편, 임상현장에서의 예측검사 도입은 증가 추세에 있으며, 특히 암 위험도 패널과 다유전자 검사의 경우 FDA 승인 제품과 의사의 수용성 확대에 힘입어 증가하고 있습니다. 데이터 프라이버시와 비즈니스 모델의 지속가능성에 대한 도전은 있지만, 미국은 여전히 예측 유전자 검사에서 가장 영향력 있는 시장입니다.

비교 기업 분석에서는 예측 유전자 검사 시장을 제품 포트폴리오(제품 만족도, 제품 기능, 가용성), 최근 시장 동향(합병/인수, 신제품 출시/개선, 투자/자금 조달, 수상, 계약/제휴/협력, 인지도, 사업 확장), 지리적 전개에 따라 평가/분류하여 의사결정과 경쟁 구도의 이해를 돕고 있습니다. 지원합니다. 이 보고서는 세계 예측 유전자 검사 시장의 주요 업체들의 최근 주요 동향과 혁신에 대한 철저한 검증을 제공합니다. 주요 시장 기업으로는 Illumina, 23andMe Holding, F. Hoffman La Roche, Ambry Genetics, Myriad Genetics, Exact Sciences, Laboratory Corporation of America Holdings, Quest Diagnostics, Thermo Fisher Scientific, NeoGenomics, Thermo Fisher Scientific, NeoGenomics, Inc. Quest Diagnostics, Thermo Fisher Scientific, NeoGenomics 등이 있습니다.

유형별로 예측 유전자 검사 시장은 '소인검사'와 '무증상기 검사'로 구분됩니다. 2024년에는 소인 검사 부문이 더 큰 시장 점유율을 차지했습니다. 이는 질병 위험의 조기 파악에 대한 관심 증가, 유전자 시퀀싱 기술의 발전, 예방의학에 대한 관심 증가로 인해 소비자가 자신의 라이프스타일을 개별적으로 계획하고 능동적으로 의료적 의사결정을 내릴 수 있게 되었기 때문입니다.

질병별로 예측 유전자 검사 시장은 암, 심혈관 질환, 대사성 질환, 기타 질환으로 분류됩니다. 2024년에는 암 부문이 예측 유전자 검사 시장에서 가장 큰 점유율을 차지했습니다. 예측 유전자 검사는 부모로부터 물려받은 암 위험을 높이는 돌연변이를 확인합니다. 이를 통해 조기발견, 예방, 개인별 맞춤치료가 가능해집니다.

최종 사용자별로 예측 유전자 검사 시장은 병원 내 검사실, 진단실험실, 기타 최종 사용자로 구분됩니다. 2024년에는 병원 내 검사실 부문이 더 큰 시장 점유율을 차지했습니다. 병원 내 검사실은 통합된 유전자 워크플로우, 정밀의료의 확대, 첨단 시퀀싱 기술 도입, 임상의와의 협력, 인식 증가, 유전적 위험의 조기 발견에 대한 수요 증가로 인해 성장하고 있습니다.

예측 유전자 검사 시장에서 사업을 전개하는 기업들은 다양한 유기적, 무기적 성장 전략을 채택하고 있습니다. 유기적 성장 전략으로는 주로 제품 출시와 제품 승인을 들 수 있습니다. 시장에서 확인되는 무기적 성장 전략에는 인수, 공동연구, 제휴 등이 있습니다. 이러한 성장 전략을 통해 시장 기업은 사업을 확장하고, 지리적 입지를 강화하며, 전체 시장 성장에 기여할 수 있습니다. 또한, 인수 및 제휴를 통해 고객 기반을 강화하고 제품 포트폴리오를 확장하는 데 기여했습니다. 다음은 예측 유전자 검사 시장의 주요 기업의 주요 개발 사항 중 일부를 소개합니다.

2025년 1월, 23andMe Holding Co.는 Discover23의 시작을 발표했습니다. 이는 새로운 조사 서비스로, 공인된 협력 기관이 세계 유수의 생의학 연구기관과 정부로부터 신뢰받는 기술 기업 Lifebit이 개발한 '신뢰할 수 있는 연구 환경(TRE)'을 통해 23andMe 연구 코호트의 힘과 다양성에 안전하게 접근할 수 있는 새로운 조사 서비스입니다.

2023년 10월, 23andMe 홀딩스는 '헬스 실행 계획'을 시작했습니다. 유전자 검사 결과, 건강 이력 조사 데이터, 혈액 및 바이오마커 데이터를 통합하여 회원에게 개인화된 건강 추천을 제공하는 새로운 디지털 도구입니다.

2023년 4월, 앰브리 제네틱스는 라이프스트랜즈 제네믹스(LifeStrands Genomics)와 제휴를 맺고 싱가포르에서 임상 유전자 검사 서비스를 제공하기 시작했습니다. 양사는 싱가포르 국가 정밀의료(NPM) 프로그램 2단계 임상 도입 파일럿(CIP)을 지원할 예정입니다.

2023년 1월, 앰브리 제네틱스는 유니랩과 제휴하여 유럽, 라틴아메리카, 중동의 바이오 제약 기업을 위한 유전자 검사 서비스를 강화했습니다. 물리적 거점이 없는 이들 시장에 유니랩의 유전체 검사 서비스와 변이체 해석 기술을 활용해 대응합니다. 한편, 앰브리는 유니랩에 자체 변이체 평가 기술을 제공합니다.

예측 유전자 검사 시장-주요 시장 역학
시장 성장 촉진요인
- 유전성 질환 증가 경향
- 맞춤형 의료에 대한 인지도와 수용성 향상
- 소비자용 직접 유전자 검사(DTC) 수요 급증
시장 성장 억제요인
- 예측 유전자 검사 사회적·윤리적 과제
- 유전자 검사 서비스 고비용
- 엄격한 규제 요건과 지연 하기 십상인 제품 승인 프로세스
시장 기회
- 도상국 미개척 신흥 시장
- 희귀질환 및 보인자 스크리닝 구상에 대한 수용도와 자금조달 증가
- 자택용 검사 키트 보급 확대
향후 동향
- 인공지능을 활용한 유전자 검사
- 유전자 검사 차세대 시퀀싱(NGS) 및 중합효소 연쇄반응(PCR) 기술 보급
- 질환 조기 발견에 수요 증가
성장 촉진요인과 억제요인의 영향

제6장 예측 유전자 검사 시장-세계 시장 분석

예측 유전자 검사 시장 매출(2021년-2031년)
예측 유전자 검사 시장 예측 분석

제7장 예측 유전자 검사 시장 분석-유형별

소인 검사
전 증상 검사

제8장 예측 유전자 검사 시장 분석-질환별

암
심혈관질환
대사성 질환
기타 질환

제9장 예측 유전자 검사 시장 분석-최종사용자별

병원내 검사실
진단실험실
기타 최종사용자

제10장 예측 유전자 검사 시장-지역 분석

북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 아시아태평양 기타 국가
중동 및 아프리카
- 사우디아라비아
- 남아프리카공화국
- 아랍에미리트
- 기타 중동 및 아프리카
남미 및 중남미
- 브라질
- 아르헨티나
- 기타 남미·중앙아메리카 기타 지역

제11장 경쟁 구도

주요 기업별 히트맵 분석
기업 점유율 분석(2024년)

제12장 업계 상황

시장 이니셔티브
인수합병(M&A)
기타 동향

제13장 기업 개요

andMe Holding Co
F. Hoffmann-La Roche Ltd
Illumina, Inc
Ambry Genetics Corp
Myriad Genetics Inc
Exact Sciences Corp
Laboratory Corp of America Holdings
Quest Diagnostics Inc
Thermo Fisher Scientific Inc.
NeoGenomics Inc

제14장 부록

LSH 26.01.22

The predictive genetic testing market is projected to reach US$ 4.20 billion by 2031 from US$ 1.42 billion in 2024. The market is projected to register a CAGR of 17.1% from 2025 to 2031. Major factors driving market growth include the rising prevalence of genetic diseases, increasing awareness and acceptance of personalized medicines, and surging preference for direct-to-consumer (DTC) genetic testing. They are propelling the acceptance of predictive genetic testing. Furthermore, increasing acceptance and funding for rare disease and carrier screening initiatives is expected to drive market growth during the forecast period. However, social and ethical implications of predictive genetic testing, high cost of genetic testing services, stringent regulatory requirements and slow product approval processes are among the market deterrents.

In the US, predictive genetic testing is deeply integrated into consumer wellness and clinical healthcare. The nation leads globally, driven by large genomics companies such as 23andMe, Myriad Genetics, and Invitae. The Genetic Information Non-discrimination Act (GINA) helps protect individuals from discrimination based on genetic risk in health insurance and employment, encouraging use of predictive testing. However, consumer genetic testing remains under scrutiny. In 2025, over two dozen states filed a lawsuit against 23andMe over its plan to sell customer genetic data amid its bankruptcy proceedings, highlighting data privacy concerns. Meanwhile, the adoption of predictive tests in clinical settings is rising, particularly for cancer risk panels and multigene tests, supported by FDA-authorized offerings and growing physician acceptance. Despite challenges around data privacy and business model sustainability, the US remains the most influential market for predictive genetic testing.

The comparative company analysis evaluates and categorizes the predictive genetic testing market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report thoroughly examines the recent significant developments and innovations by leading vendors in the global predictive genetic testing market. The key market players include Illumina, Inc, 23andMe Holding Co, F. Hoffmann-La Roche Ltd, Ambry Genetics Corp, Myriad Genetics Inc, Exact Sciences Corp, Laboratory Corp of America Holdings, Quest Diagnostics Inc, Thermo Fisher Scientific Inc., NeoGenomics Inc.

In terms of type, the predictive genetic testing market is segmented into predispositional testing and presymptomatic testing. The predispositional testing segment held a larger market share in 2024, owing to growing focus on early disease risk identification, the advances in genetic sequencing, and the rising interest in preventive healthcare give consumers the freedom to plan their lifestyle in a personalized way and to make their medical decisions proactively.

Based on disease, the predictive genetic testing market is categorized into cancer, cardiovascular diseases, metabolic diseases, and other diseases. The cancer segment accounted for the largest share of the predictive genetic testing market in 2024. Predictive genetic testing locates mutations that are passed down from the parents and increase the risk of cancer. In this way, methods for early detection, prevention, and personalized treatment become available.

Based on end-user, the predictive genetic testing market is segmented into hospital-based laboratories, diagnostic laboratories, and other end users. The hospital-based laboratories segment held a larger market share in 2024. Hospital-based laboratories are growing due to integrated genetic workflows, the expansion of precision medicine, the adoption of advanced sequencing, clinician collaboration, rising awareness, and an increasing demand for early hereditary risk detection.

Companies operating in the predictive genetic testing market adopt various organic and inorganic strategies. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies enable market players to expand their businesses, enhance their geographic presence, and contribute to overall market growth. Furthermore, acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. The following are a few significant developments by key players in the Predictive genetic testing market.

In January 2025, 23andMe Holding Co. announced the launch of Discover23, new research offering enabling authorized collaborators to securely access the power and diversity of the 23andMe research cohort through a Trusted Research Environment (TRE) developed by Lifebit, a technology company trusted by some of the world's leading biomedical research organizations and governments.

In October 2023, 23andMe Holding Co launched Health Action Plan, a new digital tool that utilizes results from genetic reports, health history survey data, and blood and biomarker data to provide a tailored set of health recommendations to its members.

In April 2023, Ambry Genetics Corp collaborated with LifeStrands Genomics to offer clinical genetic testing services in Singapore. Both the companies will support the Clinical Implementation Pilots (CIPs) for Phase II of Singapore's National Precision Medicine (NPM) programme.

In January 2023, Ambry Genetics Corp partnered with Unilabs to enhance genetic testing services for biopharma businesses in Europe, Latin America, and the Middle East, where it does not have a physical presence. It will cater to these markets by utilising Unilabs' genomic lab services and variant interpretation skills. Ambry, on the other hand, will provide Unilabs with its variant assessment skills.

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
3.3 Assumptions and Limitations

4. Predictive Genetic Testing Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 List of Vendors in the Value Chain

5. Predictive Genetic Testing Market - Key Market Dynamics

5.1 Predictive Genetic Testing Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Rising Prevalence of Genetic Diseases
- 5.2.2 Increasing Awareness and Acceptance of Personalized Medicines
- 5.2.3 Surging Preference for Direct-To-Consumer (DTC) Genetic Testing
5.3 Market Restraints
- 5.3.1 Social and Ethical Implications of Predictive Genetic Testing
- 5.3.2 High Cost of Genetic Testing Services
- 5.3.3 Stringent Regulatory Requirements and Slow Product Approval Processes
5.4 Market Opportunities
- 5.4.1 Untapped Emerging Markets in Developing Countries
- 5.4.2 Increasing Acceptance and Funding for Rare Disease and Carrier Screening Initiatives
- 5.4.3 Expansion of At-Home Testing Kits
5.5 Future Trends
- 5.5.1 Artificial Intelligence-Powered Genetic Testing
- 5.5.2 Widespread Adoption of NGS and PCR Technologies in Genetic Testing
- 5.5.3 Rising Demand for Early Disease Detection
5.6 Impact of Drivers and Restraints:

6. Predictive Genetic Testing Market - Global Market Analysis

6.1 Predictive Genetic Testing Market Revenue (US$ Million), 2021-2031
6.2 Predictive Genetic Testing Market Forecast Analysis

7. Predictive Genetic Testing Market Analysis - by Type

7.1 Predispositional Testing
- 7.1.1 Overview
- 7.1.2 Predispositional Testing: Predictive Genetic Testing Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Presymptomatic Testing
- 7.2.1 Overview
- 7.2.2 Presymptomatic Testing: Predictive Genetic Testing Market - Revenue and Forecast to 2031 (US$ Million)

8. Predictive Genetic Testing Market Analysis - by Disease

8.1 Cancer
- 8.1.1 Overview
- 8.1.2 Cancer: Predictive Genetic Testing Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Cardiovascular Diseases
- 8.2.1 Overview
- 8.2.2 Cardiovascular Diseases: Predictive Genetic Testing Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Metabolic Diseases
- 8.3.1 Overview
- 8.3.2 Metabolic Diseases: Predictive Genetic Testing Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Other Diseases
- 8.4.1 Overview
- 8.4.2 Other Diseases: Predictive Genetic Testing Market - Revenue and Forecast to 2031 (US$ Million)

9. Predictive Genetic Testing Market Analysis - by End User

9.1 Hospital-Based Laboratories
- 9.1.1 Overview
- 9.1.2 Hospital-Based Laboratories: Predictive Genetic Testing Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Diagnostic Laboratories
- 9.2.1 Overview
- 9.2.2 Diagnostic Laboratories: Predictive Genetic Testing Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Other End Users
- 9.3.1 Overview
- 9.3.2 Other End Users: Predictive Genetic Testing Market - Revenue and Forecast to 2031 (US$ Million)

10. Predictive Genetic Testing Market - Geographical Analysis

10.1 North America
- 10.1.1 North America Predictive Genetic Testing Market Overview
- 10.1.2 North America: Predictive Genetic Testing Market - Revenue, 2021-2031 (US$ Million)
  - 10.1.2.1 North America: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by Type
  - 10.1.2.2 North America: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by Disease
  - 10.1.2.3 North America: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by End User
- 10.1.3 North America: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by Country
  - 10.1.3.1 United States: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.3.1.1 United States: Predictive Genetic Testing Market Breakdown, by Type
    - 10.1.3.1.2 United States: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.1.3.1.3 United States: Predictive Genetic Testing Market Breakdown, by End User
  - 10.1.3.2 Canada: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.3.2.1 Canada: Predictive Genetic Testing Market Breakdown, by Type
    - 10.1.3.2.2 Canada: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.1.3.2.3 Canada: Predictive Genetic Testing Market Breakdown, by End User
  - 10.1.3.3 Mexico: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.1.3.3.1 Mexico: Predictive Genetic Testing Market Breakdown, by Type
    - 10.1.3.3.2 Mexico: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.1.3.3.3 Mexico: Predictive Genetic Testing Market Breakdown, by End User
10.2 Europe
- 10.2.1 Europe Predictive Genetic Testing Market Overview
- 10.2.2 Europe: Predictive Genetic Testing Market - Revenue, 2021-2031 (US$ Million)
  - 10.2.2.1 Europe: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by Type
  - 10.2.2.2 Europe: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by Disease
  - 10.2.2.3 Europe: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by End User
- 10.2.3 Europe: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by Country
  - 10.2.3.1 Germany: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.1.1 Germany: Predictive Genetic Testing Market Breakdown, by Type
    - 10.2.3.1.2 Germany: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.2.3.1.3 Germany: Predictive Genetic Testing Market Breakdown, by End User
  - 10.2.3.2 United Kingdom: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.2.1 United Kingdom: Predictive Genetic Testing Market Breakdown, by Type
    - 10.2.3.2.2 United Kingdom: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.2.3.2.3 United Kingdom: Predictive Genetic Testing Market Breakdown, by End User
  - 10.2.3.3 France: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.3.1 France: Predictive Genetic Testing Market Breakdown, by Type
    - 10.2.3.3.2 France: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.2.3.3.3 France: Predictive Genetic Testing Market Breakdown, by End User
  - 10.2.3.4 Italy: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.4.1 Italy: Predictive Genetic Testing Market Breakdown, by Type
    - 10.2.3.4.2 Italy: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.2.3.4.3 Italy: Predictive Genetic Testing Market Breakdown, by End User
  - 10.2.3.5 Spain: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.5.1 Spain: Predictive Genetic Testing Market Breakdown, by Type
    - 10.2.3.5.2 Spain: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.2.3.5.3 Spain: Predictive Genetic Testing Market Breakdown, by End User
  - 10.2.3.6 Rest of Europe: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.6.1 Rest of Europe: Predictive Genetic Testing Market Breakdown, by Type
    - 10.2.3.6.2 Rest of Europe: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.2.3.6.3 Rest of Europe: Predictive Genetic Testing Market Breakdown, by End User
10.3 Asia Pacific
- 10.3.1 Asia Pacific Predictive Genetic Testing Market Overview
- 10.3.2 Asia Pacific: Predictive Genetic Testing Market - Revenue, 2021-2031 (US$ Million)
  - 10.3.2.1 Asia Pacific: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by Type
  - 10.3.2.2 Asia Pacific: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by Disease
  - 10.3.2.3 Asia Pacific: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by End User
- 10.3.3 Asia Pacific: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by Country
  - 10.3.3.1 China: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.1.1 China: Predictive Genetic Testing Market Breakdown, by Type
    - 10.3.3.1.2 China: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.3.3.1.3 China: Predictive Genetic Testing Market Breakdown, by End User
  - 10.3.3.2 Japan: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.2.1 Japan: Predictive Genetic Testing Market Breakdown, by Type
    - 10.3.3.2.2 Japan: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.3.3.2.3 Japan: Predictive Genetic Testing Market Breakdown, by End User
  - 10.3.3.3 India: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.3.1 India: Predictive Genetic Testing Market Breakdown, by Type
    - 10.3.3.3.2 India: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.3.3.3.3 India: Predictive Genetic Testing Market Breakdown, by End User
  - 10.3.3.4 Australia: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.4.1 Australia: Predictive Genetic Testing Market Breakdown, by Type
    - 10.3.3.4.2 Australia: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.3.3.4.3 Australia: Predictive Genetic Testing Market Breakdown, by End User
  - 10.3.3.5 South Korea: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.5.1 South Korea: Predictive Genetic Testing Market Breakdown, by Type
    - 10.3.3.5.2 South Korea: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.3.3.5.3 South Korea: Predictive Genetic Testing Market Breakdown, by End User
  - 10.3.3.6 Rest of APAC: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.6.1 Rest of APAC: Predictive Genetic Testing Market Breakdown, by Type
    - 10.3.3.6.2 Rest of APAC: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.3.3.6.3 Rest of APAC: Predictive Genetic Testing Market Breakdown, by End User
10.4 Middle East and Africa
- 10.4.1 Middle East and Africa Predictive Genetic Testing Market Overview
- 10.4.2 Middle East and Africa: Predictive Genetic Testing Market - Revenue, 2021-2031 (US$ Million)
  - 10.4.2.1 Middle East and Africa: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by Type
  - 10.4.2.2 Middle East and Africa: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by Disease
  - 10.4.2.3 Middle East and Africa: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by End User
- 10.4.3 Middle East and Africa: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by Country
  - 10.4.3.1 Saudi Arabia: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.3.1.1 Saudi Arabia: Predictive Genetic Testing Market Breakdown, by Type
    - 10.4.3.1.2 Saudi Arabia: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.4.3.1.3 Saudi Arabia: Predictive Genetic Testing Market Breakdown, by End User
  - 10.4.3.2 South Africa: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.3.2.1 South Africa: Predictive Genetic Testing Market Breakdown, by Type
    - 10.4.3.2.2 South Africa: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.4.3.2.3 South Africa: Predictive Genetic Testing Market Breakdown, by End User
  - 10.4.3.3 United Arab Emirates: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.3.3.1 United Arab Emirates: Predictive Genetic Testing Market Breakdown, by Type
    - 10.4.3.3.2 United Arab Emirates: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.4.3.3.3 United Arab Emirates: Predictive Genetic Testing Market Breakdown, by End User
  - 10.4.3.4 Rest of Middle East and Africa: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.3.4.1 Rest of Middle East and Africa: Predictive Genetic Testing Market Breakdown, by Type
    - 10.4.3.4.2 Rest of Middle East and Africa: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.4.3.4.3 Rest of Middle East and Africa: Predictive Genetic Testing Market Breakdown, by End User
10.5 South and Central America
- 10.5.1 South and Central America Predictive Genetic Testing Market Overview
- 10.5.2 South and Central America: Predictive Genetic Testing Market - Revenue, 2021-2031 (US$ Million)
  - 10.5.2.1 South and Central America: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by Type
  - 10.5.2.2 South and Central America: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by Disease
  - 10.5.2.3 South and Central America: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by End User
- 10.5.3 South and Central America: Predictive Genetic Testing Market - Revenue and Forecast Analysis - by Country
  - 10.5.3.1 Brazil: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.3.1.1 Brazil: Predictive Genetic Testing Market Breakdown, by Type
    - 10.5.3.1.2 Brazil: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.5.3.1.3 Brazil: Predictive Genetic Testing Market Breakdown, by End User
  - 10.5.3.2 Argentina: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.3.2.1 Argentina: Predictive Genetic Testing Market Breakdown, by Type
    - 10.5.3.2.2 Argentina: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.5.3.2.3 Argentina: Predictive Genetic Testing Market Breakdown, by End User
  - 10.5.3.3 Rest of South and Central America: Predictive Genetic Testing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.3.3.1 Rest of South and Central America: Predictive Genetic Testing Market Breakdown, by Type
    - 10.5.3.3.2 Rest of South and Central America: Predictive Genetic Testing Market Breakdown, by Disease
    - 10.5.3.3.3 Rest of South and Central America: Predictive Genetic Testing Market Breakdown, by End User

11. Competitive Landscape

11.1 Heat Map Analysis by Key Players
11.2 Company Market Share Analysis, 2024

12. Industry Landscape

12.1 Overview
12.2 Market Initiative
12.3 Merger and Acquisition
12.4 Other Developments

13. Company Profiles

13.1andMe Holding Co
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 F. Hoffmann-La Roche Ltd
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Illumina, Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Ambry Genetics Corp
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Myriad Genetics Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Exact Sciences Corp
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Laboratory Corp of America Holdings
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Quest Diagnostics Inc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Thermo Fisher Scientific Inc.
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 NeoGenomics Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 List of Abbreviations